Abstract
We evaluated the level of MCL1 gene expression using quantitative reverse transcription polymerase chain reaction in lymph nodes of patients with non-Hodgkin lymphoma (NHL). MCL1 expression in patients in complete remission (CR) was significantly lower than in patients with progressive disease (PD, P = 0.0043). The disease-free survival rate was significantly higher in patients with MCL1 levels below the median level (P = 0.007). We also found that the level of expression of MCL1 mRNA was related to that of vascular endothelial growth factor mRNA in NHL lymph nodes. Our data suggest that the MCL1 expression level could be considered a prognostic factor in NHL.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Disease Progression
-
Disease-Free Survival
-
Endothelial Growth Factors / genetics*
-
Female
-
Gene Expression
-
Humans
-
Lymph Nodes / chemistry
-
Lymphokines / genetics*
-
Lymphoma, Non-Hodgkin / genetics*
-
Lymphoma, Non-Hodgkin / mortality
-
Male
-
Middle Aged
-
Myeloid Cell Leukemia Sequence 1 Protein
-
Neoplasm Proteins / genetics*
-
Prognosis
-
Proto-Oncogene Proteins c-bcl-2*
-
RNA, Messenger / analysis*
-
Reverse Transcriptase Polymerase Chain Reaction
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors
Substances
-
Endothelial Growth Factors
-
Lymphokines
-
Myeloid Cell Leukemia Sequence 1 Protein
-
Neoplasm Proteins
-
Proto-Oncogene Proteins c-bcl-2
-
RNA, Messenger
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors